Compound Radar

Johnson & Johnson (JNJ) Stock Analysis

Price $268.73
Market cap $646.92B
Entry status Watch $224.46–$241.96

Last updated Oct 27, 2026

Health Check

Last analyzed Oct 23, 2026

69
69/100 High Quality
  • Financial Health 65
  • Profitability 60
  • Business Quality 80
  • Balance Sheet 65
  • Cash Flow 70

Why this rating?

Health 69/100 — High Quality

Strongest Business Quality 80/100
Softest Profitability 60/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Johnson & Johnson (JNJ) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Johnson & Johnson 69/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Fair

Financial highlights

Valuation

  • P/E 40.78
  • Forward P/E 23.13
  • PEG 3
  • EV/Revenue 6.79

Profitability

  • Revenue Growth 5.9%
  • Gross Margin 67.8%
  • Operating Margin 25.7%
  • Net Margin 16.2%
  • ROE 20.0%

Financial strength

  • Cash $17.23B
  • Debt $44.65B
  • Net Cash $-27.42B
  • Free Cash Flow $19.31B
  • Current Ratio 1.02

Similar companies

Peers in Drug Manufacturers - General, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - General →

FAQ

How Compound Radar scores and tracks Johnson & Johnson (JNJ).

View Methodology & FAQ →